temozolomide has been researched along with Anaplastic Ependymoma in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib." | 9.41 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. ( Aldape, K; Armstrong, TS; Gerstner, ER; Gilbert, MR; Lieberman, F; Mendoza, T; Mikkelsen, T; Omuro, A; Robins, HI; Vera, E; Wen, PY; Wu, J; Yuan, Y, 2021) |
| "Few data are available on temozolomide (TMZ) in ependymomas." | 7.83 | Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. ( Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M, 2016) |
| "Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties." | 7.80 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. ( Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T, 2014) |
| "Myxopapillary ependymomas are intradural tumors which grow from the terminal filum of the spinal cord." | 6.58 | Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( Adachi, N; Fujiwara, Y; Izumi, B; Manabe, H; Shima, T, 2018) |
| "Apatinib is a multitarget tyrosine kinase inhibitor, which has been reported to exhibit broad antitumor profiles." | 5.72 | Apatinib and temozolomide in children with recurrent ependymoma: A case report. ( Li, J; Shen, Z; Shi, L; Zhang, N; Zhao, S, 2022) |
| "Patients age 18 or older with histologically proven and progressive ependymoma or anaplastic ependymoma were eligible and received dose-dense TMZ and daily lapatinib." | 5.41 | A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. ( Aldape, K; Armstrong, TS; Gerstner, ER; Gilbert, MR; Lieberman, F; Mendoza, T; Mikkelsen, T; Omuro, A; Robins, HI; Vera, E; Wen, PY; Wu, J; Yuan, Y, 2021) |
| "Anaplastic ependymomas are rare tumors in adult patients." | 5.39 | Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( Bellu, L; Della Puppa, A; Gardiman, MP; Lombardi, G; Pambuku, A; Pomerri, F; Rumanò, L; Zagonel, V, 2013) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 5.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| "Although overall objective responses were limited, further exploration of temozolomide may be warranted in children with medulloblastoma and other PNETs, or in patients with low-grade astrocytoma, perhaps in a setting of less pretreatment than the patients in the current study, or in the context of multiagent therapy." | 5.12 | Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. ( Bernstein, M; Fort, D; Friedman, H; Harris, MB; Kadota, R; Krailo, M; Kretschmar, CS; Mazewski, C; Nicholson, HS; Reaman, GH; Sato, J; Tedeschi-Blok, N, 2007) |
| "Using data from the German multi-center E-HIT-REZ-2005 study, we examined the role of local therapy and the efficacy of chemotherapy with blockwise temozolomide (TMZ) in children and adolescents with recurrent ependymomas." | 4.02 | Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. ( Adolph, JE; Bison, B; Bode, U; Faldum, A; Fleischhack, G; Frühwald, MC; Kortmann, RD; Krauß, J; Kwiecien, R; Mikasch, R; Mynarek, M; Obrecht, D; Pajtler, KW; Pfister, SM; Pietsch, T; Rutkowski, S; Schüller, U; Timmermann, B; Tippelt, S; von Hoff, K; Warmuth-Metz, M; Witt, H; Witt, O; Zeller, J, 2021) |
| "Few data are available on temozolomide (TMZ) in ependymomas." | 3.83 | Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. ( Bosa, C; Cassoni, P; Fiano, V; Franchino, F; Magistrello, M; Pellerino, A; Rudà, R; Soffietti, R; Trevisan, M, 2016) |
| "Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties." | 3.80 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. ( Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T, 2014) |
| "Myxopapillary ependymomas are intradural tumors which grow from the terminal filum of the spinal cord." | 2.58 | Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review. ( Adachi, N; Fujiwara, Y; Izumi, B; Manabe, H; Shima, T, 2018) |
| "Apatinib is a multitarget tyrosine kinase inhibitor, which has been reported to exhibit broad antitumor profiles." | 1.72 | Apatinib and temozolomide in children with recurrent ependymoma: A case report. ( Li, J; Shen, Z; Shi, L; Zhang, N; Zhao, S, 2022) |
| "Anaplastic ependymomas are rare tumors in adult patients." | 1.39 | Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. ( Bellu, L; Della Puppa, A; Gardiman, MP; Lombardi, G; Pambuku, A; Pomerri, F; Rumanò, L; Zagonel, V, 2013) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 1.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, S | 1 |
| Shen, Z | 1 |
| Li, J | 1 |
| Shi, L | 1 |
| Zhang, N | 1 |
| Gilbert, MR | 1 |
| Yuan, Y | 1 |
| Wu, J | 2 |
| Mendoza, T | 1 |
| Vera, E | 1 |
| Omuro, A | 1 |
| Lieberman, F | 1 |
| Robins, HI | 1 |
| Gerstner, ER | 1 |
| Wen, PY | 1 |
| Mikkelsen, T | 1 |
| Aldape, K | 1 |
| Armstrong, TS | 1 |
| Adolph, JE | 1 |
| Fleischhack, G | 1 |
| Mikasch, R | 1 |
| Zeller, J | 1 |
| Warmuth-Metz, M | 1 |
| Bison, B | 1 |
| Mynarek, M | 1 |
| Rutkowski, S | 1 |
| Schüller, U | 1 |
| von Hoff, K | 1 |
| Obrecht, D | 1 |
| Pietsch, T | 1 |
| Pfister, SM | 1 |
| Pajtler, KW | 1 |
| Witt, O | 1 |
| Witt, H | 1 |
| Kortmann, RD | 1 |
| Timmermann, B | 1 |
| Krauß, J | 1 |
| Frühwald, MC | 1 |
| Faldum, A | 1 |
| Kwiecien, R | 1 |
| Bode, U | 1 |
| Tippelt, S | 1 |
| Fujiwara, Y | 1 |
| Manabe, H | 1 |
| Izumi, B | 1 |
| Shima, T | 1 |
| Adachi, N | 1 |
| Lombardi, G | 1 |
| Pambuku, A | 1 |
| Bellu, L | 1 |
| Della Puppa, A | 1 |
| Rumanò, L | 1 |
| Gardiman, MP | 1 |
| Pomerri, F | 1 |
| Zagonel, V | 1 |
| Meco, D | 1 |
| Servidei, T | 1 |
| Lamorte, G | 1 |
| Binda, E | 1 |
| Arena, V | 1 |
| Riccardi, R | 1 |
| Komori, K | 1 |
| Yanagisawa, R | 1 |
| Miyairi, Y | 1 |
| Sakashita, K | 1 |
| Shiohara, M | 1 |
| Fujihara, I | 1 |
| Morita, D | 1 |
| Nakamura, T | 1 |
| Ogiso, Y | 1 |
| Sano, K | 1 |
| Shirahata, M | 1 |
| Fukuoka, K | 1 |
| Ichimura, K | 1 |
| Shigeta, H | 1 |
| Rudà, R | 1 |
| Bosa, C | 1 |
| Magistrello, M | 1 |
| Franchino, F | 1 |
| Pellerino, A | 1 |
| Fiano, V | 1 |
| Trevisan, M | 1 |
| Cassoni, P | 1 |
| Soffietti, R | 1 |
| Gramatzki, D | 1 |
| Roth, P | 1 |
| Felsberg, J | 1 |
| Hofer, S | 1 |
| Rushing, EJ | 1 |
| Hentschel, B | 1 |
| Westphal, M | 1 |
| Krex, D | 1 |
| Simon, M | 1 |
| Schnell, O | 1 |
| Wick, W | 1 |
| Reifenberger, G | 1 |
| Weller, M | 1 |
| Chamberlain, MC | 1 |
| Johnston, SK | 1 |
| Freyschlag, CF | 1 |
| Tuettenberg, J | 1 |
| Lohr, F | 1 |
| Thomé, C | 1 |
| Schmieder, K | 1 |
| Seiz, M | 1 |
| Salameire, D | 1 |
| Khoo, HM | 1 |
| Kishima, H | 1 |
| Kinoshita, M | 1 |
| Goto, Y | 1 |
| Kagawa, N | 1 |
| Hashimoto, N | 1 |
| Maruno, M | 1 |
| Yoshimine, T | 1 |
| Vos, MJ | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 1 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 1 |
| Rojas-Marcos, I | 1 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Delattre, JY | 1 |
| Rehman, S | 1 |
| Brock, C | 1 |
| Newlands, ES | 1 |
| Nicholson, HS | 1 |
| Kretschmar, CS | 1 |
| Krailo, M | 1 |
| Bernstein, M | 1 |
| Kadota, R | 1 |
| Fort, D | 1 |
| Friedman, H | 1 |
| Harris, MB | 1 |
| Tedeschi-Blok, N | 1 |
| Mazewski, C | 1 |
| Sato, J | 1 |
| Reaman, GH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma[NCT00028795] | Phase 2 | 170 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway[NCT01601184] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2012-06-30 | Terminated (stopped due to The number of successes is not reached at the end of first stage of the phase II. The study is stopped.) | ||
| A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2013-10-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for temozolomide and Anaplastic Ependymoma
| Article | Year |
|---|---|
Remarkable efficacy of temozolomide for relapsed spinal myxopapillary ependymoma with multiple recurrence and cerebrospinal dissemination: a case report and literature review.
Topics: Adult; Antineoplastic Agents, Alkylating; Cauda Equina; Chemotherapy, Adjuvant; Combined Modality Th | 2018 |
2 trials available for temozolomide and Anaplastic Ependymoma
| Article | Year |
|---|---|
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
Topics: Adolescent; Adult; Brain Neoplasms; Dacarbazine; Disease-Free Survival; Ependymoma; Humans; Lapatini | 2021 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neopl | 2007 |
14 other studies available for temozolomide and Anaplastic Ependymoma
| Article | Year |
|---|---|
Apatinib and temozolomide in children with recurrent ependymoma: A case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Ependymoma; Humans; Male | 2022 |
Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Neoplasm Recurrence, Local; Radiotherapy, Ad | 2021 |
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cisplatin; Dacarbazine; Drug Therapy, Combination; Ependymom | 2013 |
Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; DNA Modification Me | 2014 |
Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child, Preschool; Dacarbazine; DNA Modification | 2016 |
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Fema | 2016 |
Chemotherapy for intracranial ependymoma in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis | 2016 |
Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Dacarbazine; Disease-Free Survival | 2009 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; | 2011 |
[Cutaneous neutrophils infiltrates. Case 4. Pseudo-tumoral cutaneous alternariosis].
Topics: Aged, 80 and over; Alternaria; Antifungal Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms | 2011 |
Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: a case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Cerebellar Neoplasms; Dacarbazine; Ependymoma | 2013 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Ependymoma; Female; Humans; | 2006 |